2nd Quarter - Report

THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Firm
Client
Income
—
Expenses
$2,530,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) -Issues related to H.R. 6810, the Health Care Protection Act, H.R. 6379, the Take Responsibility for Workers and Families Act, and H.R. 6514, the Worker Health Coverage Protection Act -P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -S 1323, UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; White House Office; Treasury, Dept of; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: S. 3741 (116th), H.R. 6514 (116th), H.R. 6800 (116th), H.R. 3502 (116th), H.R. 5800 (116th), S. 1895 (116th), H.R. 861 (116th), H.R. 3630 (116th), H.R. 6644 (116th), H.R. 2328 (116th), H.R. 6379 (116th), H.R. 6810 (116th)

Defense DEF

-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
BRENDAN DEVINE —
JOE DUNN —
GARY J KLINE —
LISA CHRISTINE LE GETTE —

Contacted: White House Office; SENATE; Treasury, Dept of; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 6395 (116th), S. 4049 (116th)

Medicare/Medicaid MMM

-Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Policies that impact public programs payments for high cost drugs including gene therapies.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
KRISTIN JULASON DAMATO —
GARY J KLINE —
KAREN LYNN NONNEMAKER —

Contacted: Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Treasury, Dept of

Bills named: H.R. 1035 (116th), H.R. 1034 (116th), H.R. 803 (116th), S. 640 (116th)

Pharmacy PHA

-Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Treasury, Dept of; Commerce, Dept of (DOC); White House Office

Bills named: S. 1895 (116th)

Affiliated organisations

OrganisationLocation
EXPRESS SCRIPTS, INC. St. Louis, MO, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.